Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone Vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2017) 130 (Supplement 1): 1886.

https://doi.org/10.1182/blood.V130.Suppl_1.1886.1886

Published: 2017

Journal Articles

Breast Implant Related Anaplastic Large Cell Lymphoma ALK- (ALCL ALK-) – Case Report

Alejandro Arbelaez, MBBS, Laurence Catley, MBBS, FRCPA, FRACP, Louis Pool, MBBS, FRCPA

Blood (2013) 122 (21): 5086.

https://doi.org/10.1182/blood.V122.21.5086.5086

Published: 2013

Journal Articles

Haemophagocytic Lymphohistiocytosis (HLH) Associated With a Heterozygous PRF1 Mutation Not Previously Described As Pathogenic

Alejandro Arbelaez, MBBS, Laurence Catley, MBBS, FRCPA, FRACP

Blood (2013) 122 (21): 4715.

https://doi.org/10.1182/blood.V122.21.4715.4715

Published: 2013

Journal Articles

Immunoregulation of Human Myeloid Dendritic Cells and Monocytes by Vascular Endothelial Growth Factor,

Washington Yamandu Sanchez, Jr., PhD, Ran Wang, Andrew Wilkinson, Dalia Khalil, Derek NJ Hart, MBCHB, DPhil, Laurence Catley, MBBS, FRCPA, FRACP, Slavica Vuckovic, Dr

Blood (2011) 118 (21): 3212.

https://doi.org/10.1182/blood.V118.21.3212.3212

Published: 2011

Journal Articles

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Paul G. Richardson, MD, Andrew Spencer, MD, Paul Cannell, MBBS, FRCPA, FRACP, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Laurence Catley, MBBS, FRCPA, FRACP, Craig Underhill, MBBS, FRACP, Todd M. Zimmerman, MD, Craig C. Hofmeister, MD, Andrzej J Jakubowiak, MD, PhD, Jacob P. Laubach, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Ana Lay, Sandra Wear, RN, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Steve Reich, MD, Matthew A. Spear, MD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 302.

https://doi.org/10.1182/blood.V118.21.302.302

Published: 2011

Journal Articles

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052.

Andrew Spencer, Michael Millward, MD, Paul Mainwaring, MD, Simon Harrison, MD, Laurence Catley, MBBS, FRCPA, FRACP, Amanda Townsend, MD, Shawgi Sukumaran, MD, Angie M. Longenecker, RN, BSN, Michael A. Palladino, PhD, G. Kenneth Lloyd, PhD, Saskia Neuteboom, PhD, Peeter Padrik, MD, Matthew A. Spear, MD, Timothy Price, MD

Blood (2009) 114 (22): 2693.

https://doi.org/10.1182/blood.V114.22.2693.2693

Published: 2009

Journal Articles

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL– and mutant FLT3-expressing cells

Ellen Weisberg, Lolita Banerji, Renee D. Wright, Rosemary Barrett, Arghya Ray, Daisy Moreno, Laurence Catley, Jingrui Jiang, Elizabeth Hall-Meyers, Maira Sauveur-Michel, Richard Stone, Ilene Galinsky, Edward Fox, Andrew L. Kung, James D. Griffin

Blood (2008) 111 (7): 3723–3734.

https://doi.org/10.1182/blood-2007-09-114454

Published: 2008

Includes: Supplemental data

Journal Articles

JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells

Tanyel Kiziltepe, Teru Hideshima, Kenji Ishitsuka, Enrique M. Ocio, Noopur Raje, Laurence Catley, Chun-Qi Li, Laura J. Trudel, Hiroshi Yasui, Sonia Vallet, Jeffery L. Kutok, Dharminder Chauhan, Constantine S. Mitsiades, Joseph E. Saavedra, Gerald N. Wogan, Larry K. Keefer, Paul J. Shami, Kenneth C. Anderson

Blood (2007) 110 (2): 709–718.

https://doi.org/10.1182/blood-2006-10-052845

Published: 2007

Includes: Supplemental data

Journal Articles

Novel Murine Model To Study Modulation of Genes and Molecular Pathways Induced Following In Vivo Interaction between Multiple Myeloma Cells and Human BM Milieu.

Paola Neri, MD, Pierfrancesco Tassone, MD, Masood Shammas, PhD, Mariateresa Fulciniti, PhD, Yu-Tzu Tai, PhD, Simona Blotta, MD, Rao Prabhala, PhD, Mariateresa Di Martino, PhD, Laurence Catley, MD, Pierosandro Tagliaferri, MD, Salvatore Venuta, MD, Ruben Carrasco, MD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2006) 108 (11): 3409.

https://doi.org/10.1182/blood.V108.11.3409.3409

Published: 2006

Journal Articles

Serotonin Receptor Antagonists Have an In Vitro and In Vivo Anti-Myeloma Effect That Is Mainly Mediated by Caspase Dependent Apoptosis.

Enrique M. Ocio, MD, PhD, Teru Hideshima, MD, PhD, Hiroshi Yasui, MD, PhD, Kiziltepe Tanyel, PhD, Hirosi Ikeda, MD, PhD, Yutaka Okawa, MD, PhD, Sonia Vallet, MD, Janice Jin, MD, Kenji Ishitsuka, MD, PhD, Noopur Raje, MD, Laurence Catley, MD, MBBS, FRACP, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 2597.

https://doi.org/10.1182/blood.V108.11.2597.2597

Published: 2006

Journal Articles

Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells.

Teru Hideshima, MD, PhD, Hiroshi Yasui, MD, PhD, Laurence Catley, MD, Noopur Raje, MD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Klaus Podar, MD, PhD, Constantine Mitsiades, MD, PhD, Yu-Tzu Tai, PhD, Sonia Vallet, MD, Tanyel Kizitepe, PhD, Enrique Ocio, MD, PhD, Hiroshi Ikeda, MD, PhD, Yutaka Okawa, MD, PhD, Hiromasa Hideshima, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 3410.

https://doi.org/10.1182/blood.V108.11.3410.3410

Published: 2006

Journal Articles

JS-K, a GST-Activated Nitric Oxide Generator, Induces DNA-Double Strand Breaks and Inhibits Growth and Survival of Multiple Myeloma Cells In Vitro and In Vivo .

Tanyel Kiziltepe, PhD, Teru Hideshima, Noopur Raje, Kenji Ishitsuka, Enrique M. Ocio, Laurence Catley, Chun-Qi Li, Laura Trudel, Hiroshi Yasui, Norihiko Shirashi, Yu-Tzu Tai, Dharminder Chauhan, Constantine Mitsiades, Joseph E. Saavedra, Gerald N. Wogan, Larry K. Keefer, Paul J. Shami, Kenneth C. Anderson

Blood (2006) 108 (11): 3453.

https://doi.org/10.1182/blood.V108.11.3453.3453

Published: 2006

Journal Articles

Biological Pathways and In Vivo Anti-Tumor Activity Induced by Atiprimod in Multiple Myeloma (MM).

Paola Neri, MD, Pierfrancesco Tassone, MD, Masood Shammas, PhD, Hiroshi Yasui, MD, Ernestina Schipani, MD, Ramesh B. Batchu, PhD, Simona Blotta, MD, Rao Prabhala, PhD, Laurence Catley, MD, Makoto Hamasaki, MD, Teru Hideshima, MD, Dharminder Chauhan, PhD, Gary S. Jacob, PhD, Donald Picker, PhD, Salvatore Venuta, MD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2006) 108 (11): 3455.

https://doi.org/10.1182/blood.V108.11.3455.3455

Published: 2006

Journal Articles

In Vitro Generation of Highly Purified Functional Invariant NKT Cells in Multiple Myeloma: A Strategy for Immunotherapy.

Weihua Song, MD, Hans J.J. van der Vliet, MD, Yu-Tzu Tai, PhD, Ruojie Wang, MD, Rao Prabhala, PhD, Klaus Podar, MD, Laurence Catley, MD, Masood Shammas, PhD, Steven P. Balk, MD, Kenneth C. Anderson, MD, Mark A. Exley, PhD, Nikhil C. Munshi, MD

Blood (2006) 108 (11): 5104.

https://doi.org/10.1182/blood.V108.11.5104.5104

Published: 2006

Journal Articles

Epigenetic Modulation by Vidaza™ induces Apoptosis and Overcomes In Vitro Drug Resistance in Human Multiple Myeloma Cells.

Tanyel Kiziltepe, PhD, Laurence Catley, MD, Teru Hideshima, MD,PhD, Noopur Raje, MD, Hiroshi Yasui, MD,PhD, Sonia Vallet, MD, Hiroshi Ikeda, MD,PhD, Yutaka Okawa, MD,PhD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 5001.

https://doi.org/10.1182/blood.V108.11.5001.5001

Published: 2006

Journal Articles

Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

Laurence Catley, Ellen Weisberg, Tanyel Kiziltepe, Yu-Tzu Tai, Teru Hideshima, Paola Neri, Pierfrancesco Tassone, Peter Atadja, Dharminder Chauhan, Nikhil C. Munshi, Kenneth C. Anderson

Blood (2006) 108 (10): 3441–3449.

https://doi.org/10.1182/blood-2006-04-016055

Published: 2006

Journal Articles

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

Teru Hideshima, Laurence Catley, Hiroshi Yasui, Kenji Ishitsuka, Noopur Raje, Constantine Mitsiades, Klaus Podar, Nikhil C. Munshi, Dharminder Chauhan, Paul G. Richardson, Kenneth C. Anderson

Blood (2006) 107 (10): 4053–4062.

https://doi.org/10.1182/blood-2005-08-3434

Published: 2006

Journal Articles

In Vivo Anti-Tumor Activity of Atiprimod on SCID Models of Multiple Myeloma.

Paola Neri, MD, Pierfrancesco Tassone, MD, Masood A. Shammas, PhD, Ramesh B. Batchu, PhD, Simona Blotta, MD, Sushma Samala, PhD, Laurence Catley, MD, Makoto Hamasaki, PhD, Teru Hideshima, MD, Gary S. Jacob, PhD, Donald H. Picker, PhD, Salvatore Venuta, MD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2005) 106 (11): 249.

https://doi.org/10.1182/blood.V106.11.249.249

Published: 2005

Journal Articles

Novel Model To Evaluate Changes in Gene Expression Profile of Myeloma Cells In Vivo Following Interaction with Human BM Microenvironment.

Paola Neri, MD, Pierfrancesco Tassone, MD, Masood A. Shammas, PhD, Daniel R. Carrasco, MD, Renate Burger, PhD, Constantine S. Mitsdiades, MD, Simona Blotta, MD, Rao H. Prabhala, PhD, Laurence Catley, MD, Salvatore Venuta, MD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2005) 106 (11): 2490.

https://doi.org/10.1182/blood.V106.11.2490.2490

Published: 2005

Journal Articles

Perifosine, an Oral Bioactive Novel Alkyl-Phospholipid, Inhibits Akt and Induces In Vitro and In Vivo Cytotoxicity in Human Multiple Myeloma (MM) Cells.

Teru Hideshima, MD, PhD, Laurence Catley, MD, Hiroshi Yasui, MD, PhD, Kenji Ishitsuka, MD, PhD, Noopur Raje, MD, Constantine Mitsiades, MD, PhD, Klaus Podar, MD, PhD, Nikhil C. Munshi, MD, Dharminder Chauhan, PhD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 250.

https://doi.org/10.1182/blood.V106.11.250.250

Published: 2005

NARROW

Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone Vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma

Breast Implant Related Anaplastic Large Cell Lymphoma ALK- (ALCL ALK-) – Case Report

Haemophagocytic Lymphohistiocytosis (HLH) Associated With a Heterozygous PRF1 Mutation Not Previously Described As Pathogenic

Immunoregulation of Human Myeloid Dendritic Cells and Monocytes by Vascular Endothelial Growth Factor,

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052.

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL– and mutant FLT3-expressing cells

JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells

Novel Murine Model To Study Modulation of Genes and Molecular Pathways Induced Following In Vivo Interaction between Multiple Myeloma Cells and Human BM Milieu.

Serotonin Receptor Antagonists Have an In Vitro and In Vivo Anti-Myeloma Effect That Is Mainly Mediated by Caspase Dependent Apoptosis.

Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells.

JS-K, a GST-Activated Nitric Oxide Generator, Induces DNA-Double Strand Breaks and Inhibits Growth and Survival of Multiple Myeloma Cells In Vitro and In Vivo .

Biological Pathways and In Vivo Anti-Tumor Activity Induced by Atiprimod in Multiple Myeloma (MM).

In Vitro Generation of Highly Purified Functional Invariant NKT Cells in Multiple Myeloma: A Strategy for Immunotherapy.

Epigenetic Modulation by Vidaza™ induces Apoptosis and Overcomes In Vitro Drug Resistance in Human Multiple Myeloma Cells.

Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

In Vivo Anti-Tumor Activity of Atiprimod on SCID Models of Multiple Myeloma.

Novel Model To Evaluate Changes in Gene Expression Profile of Myeloma Cells In Vivo Following Interaction with Human BM Microenvironment.

Perifosine, an Oral Bioactive Novel Alkyl-Phospholipid, Inhibits Akt and Induces In Vitro and In Vivo Cytotoxicity in Human Multiple Myeloma (MM) Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only